Safety of secukinumab treatment in COVID-19 affected psoriatic patients.
作者信息
Mugheddu Cristina, Sanna Silvia, Atzori Laura, Rongioletti Franco
机构信息
Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
出版信息
Dermatol Ther. 2021 Jan;34(1):e14710. doi: 10.1111/dth.14710. Epub 2021 Jan 3.
Abstract
摘要
相似文献
1
Safety of secukinumab treatment in COVID-19 affected psoriatic patients.司库奇尤单抗治疗新冠病毒感染的银屑病患者的安全性
Dermatol Ther. 2021 Jan;34(1):e14710. doi: 10.1111/dth.14710. Epub 2021 Jan 3.
2
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.司库奇尤单抗治疗活动性银屑病关节炎（EXCEED）：一项双盲、平行组、随机、主动对照、3b 期临床试验。
Lancet. 2020 May 9;395(10235):1496-1505. doi: 10.1016/S0140-6736(20)30564-X.
3
A review of secukinumab in psoriasis treatment.司库奇尤单抗治疗银屑病的研究进展。
Immunotherapy. 2021 Feb;13(3):201-216. doi: 10.2217/imt-2020-0195. Epub 2020 Nov 18.
4
Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis.匹配调整间接比较：司库奇尤单抗与英夫利昔单抗在生物制剂初治的银屑病关节炎患者中的比较。
J Comp Eff Res. 2019 May;8(7):497-510. doi: 10.2217/cer-2018-0141. Epub 2019 Feb 26.
5
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.司库奇尤单抗治疗中重度斑块状银屑病、银屑病关节炎和强直性脊柱炎患者的长期安全性：汇总临床试验和上市后监测数据。
Arthritis Res Ther. 2019 May 2;21(1):111. doi: 10.1186/s13075-019-1882-2.
6
Treatment of psoriatic arthritis with secukinumab: a case series.司库奇尤单抗治疗银屑病关节炎：病例系列
J Dermatolog Treat. 2018;29(sup1):6-8. doi: 10.1080/09546634.2018.1527994.
7
Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis.司库奇尤单抗治疗银屑病关节炎患者的长期疗效和安全性。
Eur J Intern Med. 2023 Dec;118:152-154. doi: 10.1016/j.ejim.2023.08.023. Epub 2023 Sep 9.
8
Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis.在一名儿科患者中使用司库奇尤单抗可显著改善指甲银屑病和银屑病关节炎。
Pediatr Dermatol. 2019 May;36(3):384-385. doi: 10.1111/pde.13767. Epub 2019 Feb 27.
9
Evaluation of the Feasibility of a Web-Based Survey to Assess Patient-Reported Symptom Improvement and Treatment Satisfaction Among Patients with Psoriatic Arthritis Receiving Secukinumab.评估基于网络的调查在评估接受司库珠单抗治疗的银屑病关节炎患者的患者报告症状改善和治疗满意度方面的可行性。
Clin Drug Investig. 2019 Dec;39(12):1205-1212. doi: 10.1007/s40261-019-00856-8.
10
Successful treatment with secukinumab of three psoriatic patients undergoing dialysis.三名正在接受透析的银屑病患者使用司库奇尤单抗治疗成功。
J Dermatol. 2020 Jan;47(1):e26-e28. doi: 10.1111/1346-8138.15132. Epub 2019 Oct 27.
引用本文的文献
1
Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database.使用美国食品和药物管理局不良事件报告系统数据库评估司库奇尤单抗在真实世界场景中的安全性概况。
Sci Rep. 2024 Jan 12;14(1):1222. doi: 10.1038/s41598-023-50013-7.
2
Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.银屑病患者接受白细胞介素-17 抑制剂治疗后感染 COVID-19、住院和死亡的风险：系统评价和荟萃分析。
Front Immunol. 2022 Oct 21;13:1046352. doi: 10.3389/fimmu.2022.1046352. eCollection 2022.
3
Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities.2019年冠状病毒病大流行期间中重度银屑病的治疗：经验教训与机遇
J Clin Med. 2022 Apr 26;11(9):2422. doi: 10.3390/jcm11092422.
4
Biologics for Psoriasis During the COVID-19 Pandemic.新冠疫情期间用于治疗银屑病的生物制剂
Front Med (Lausanne). 2021 Dec 6;8:759568. doi: 10.3389/fmed.2021.759568. eCollection 2021.
5
Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years.过去5年中司库奇尤单抗用于影像学和非影像学轴向脊柱关节炎患者的证据。
Rheumatol Ther. 2022 Feb;9(1):73-94. doi: 10.1007/s40744-021-00400-1. Epub 2021 Nov 27.
6
Clinical Dermatology and COVID-19 Pandemic: Narrative Review.临床皮肤病学与新冠疫情：叙述性综述
Indian J Dermatol. 2021 May-Jun;66(3):246-255. doi: 10.4103/ijd.ijd_463_21.
7
The Emerging Role of Neutrophils in the Pathogenesis of Thrombosis in COVID-19.中性粒细胞在 COVID-19 血栓形成发病机制中的新作用。
Int J Mol Sci. 2021 May 20;22(10):5368. doi: 10.3390/ijms22105368.
本文引用的文献
1
Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury.新冠病毒肺炎患者血浆中某些细胞因子水平升高反映了病毒载量和肺损伤。
Natl Sci Rev. 2020 Jun;7(6):1003-1011. doi: 10.1093/nsr/nwaa037. Epub 2020 Mar 9.
2
Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.以病例为基础的综述：使用司库奇尤单抗治疗的强直性脊柱炎患者的 2019 年冠状病毒病（COVID-19）。
Rheumatol Int. 2020 Oct;40(10):1707-1716. doi: 10.1007/s00296-020-04635-z. Epub 2020 Jun 26.
3
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.中重度斑块状银屑病患者真实世界队列的现状，以及在新冠疫情时代使用生物制剂的相关考虑。
Expert Opin Biol Ther. 2020 Aug;20(8):829-830. doi: 10.1080/14712598.2020.1779217. Epub 2020 Jun 16.
4
COVID-19 in an elderly patient treated with secukinumab.一位接受司库奇尤单抗治疗的老年患者的新型冠状病毒肺炎
Dermatol Ther. 2020 Jul;33(4):e13580. doi: 10.1111/dth.13580. Epub 2020 May 27.
5
Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.生物制剂增加了感染 SARS-CoV-2 和住院的风险，但不会增加 ICU 收治和死亡的风险：在红色区域宣布期间来自大型队列的真实数据。
Dermatol Ther. 2020 Sep;33(5):e13475. doi: 10.1111/dth.13475. Epub 2020 May 19.
6
Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy.严重急性呼吸综合征冠状病毒 2 感染和肺癌患者：白细胞介素 17 靶向治疗的潜在作用。
J Thorac Oncol. 2020 Jul;15(7):e101-e103. doi: 10.1016/j.jtho.2020.04.015. Epub 2020 Apr 27.
7
Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in Sardinia (Italy).新冠疫情期间的银屑病医疗保健：来自意大利撒丁岛专业中心的见解
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e247-e248. doi: 10.1111/jdv.16473. Epub 2020 Jun 4.
8
COVID-19 and immunomodulator/immunosuppressant use in dermatology.新型冠状病毒肺炎与皮肤科中免疫调节剂/免疫抑制剂的应用
J Am Acad Dermatol. 2020 May;82(5):e173-e175. doi: 10.1016/j.jaad.2020.03.046. Epub 2020 Mar 26.
9
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
Zotero 插件